表紙
市場調査レポート

PharmaPoint:髄膜炎菌ワクチン - 現在/将来の市場参入企業

PharmaPoint: Meningococcal Vaccines - Current and Future Players

発行 GlobalData 商品コード 275368
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
PharmaPoint:髄膜炎菌ワクチン - 現在/将来の市場参入企業 PharmaPoint: Meningococcal Vaccines - Current and Future Players
出版日: 2013年08月31日 ページ情報: 英文 70 Pages
概要

当レポートでは、髄膜炎菌ワクチン市場で急成長を遂げている企業について調査分析し、主要企業の現状と促進要因に焦点を当てて、競合情勢、主要企業プロファイルなどを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 促進要因・障壁

第4章 現在/将来の企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Sanofi
    • Novartis
    • GlaxoSmithKline
    • Baxter
    • Nuron Biotech
    • Pfizer

第5章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC1013FPR

GlobalData has released its pharma report, "PharmaPoint: Meningococcal Vaccines - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Meningococcal Vaccines Market. The report identifies and analyses the key companies shaping and driving the global Meningococcal Vaccines market. The report provides insight into the competitive Meningococcal Vaccines landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Meningococcal Vaccines
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the Meningococcal Vaccines sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving the Meningococcal Vaccines Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Meningococcal Vaccines market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Sanofi
    • 4.3.2. Novartis
    • 4.3.3. GlaxoSmithKline
    • 4.3.4. Baxter
    • 4.3.5. Nuron Biotech
    • 4.3.6. Pfizer

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Vaccine Coverage
    • 5.4.2. Vaccine Approval vs. Routine Schedule Inclusion
    • 5.4.3. Vaccines Included
    • 5.4.4. Key Launch Dates
    • 5.4.5. General Pricing Assumptions
    • 5.4.6. Individual Vaccine Assumptions
    • 5.4.7. Pricing of Pipeline agents
  • 5.5. Physicians and Specialists Included in this Study
  • 5.6. About the Authors
    • 5.6.1. Author(s)
    • 5.6.2. Reviewer(s)
    • 5.6.3. Epidemiologist(s)
    • 5.6.4. Global Head of Healthcare
  • 5.7. About GlobalData
  • 5.8. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for Meningococcal Vaccines, 2012-2022
  • Table 2: Global Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
  • Table 3: Key Companies in the Meningococcal Vaccines Market, 2012
  • Table 4: Sanofi's Meningococcal Vaccines Portfolio Assessment, 2012
  • Table 5: Sanofi SWOT Analysis, 2012
  • Table 6: Novartis' Meningococcal Vaccines Portfolio Assessment, 2012
  • Table 7: Novartis SWOT Analysis, 2012
  • Table 8: GSK's Meningococcal Vaccines Portfolio Assessment, 2012
  • Table 9: GSK SWOT Analysis, 2012
  • Table 10: Baxter's Meningococcal Vaccines Portfolio Assessment, 2012
  • Table 11: Baxter SWOT Analysis, 2012
  • Table 12: Nuron Biotech's Meningococcal Vaccines Portfolio Assessment, 2012
  • Table 13: Nuron Biotech SWOT Analysis, 2012
  • Table 14: Pfizer's Meningococcal Vaccines Portfolio Assessment, 2012
  • Table 15: Pfizer SWOT Analysis, 2012
  • Table 16: Key Launch Dates
  • Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for Meningococcal Vaccines by Region, 2012-2022
  • Figure 2: Company Portfolio Gap Analysis in Meningococcal Vaccines, 2012-2022
Back to Top